Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our findings indicate an important role of TNFα-IKK-YAP/p65-HK2 signaling axis in the process of inflammation-driven migration in breast cancer cells, which reveals a new molecular link between inflammation and breast cancer metastasis.
|
28945218 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both epinephrine (EPI) and norepinephrine (NE) could directly inhibit breast cancer cell viability, as well as tumor growth <i>in vivo</i> EPI and NE activate the tumor suppressor Hippo signaling pathway, and the suppressive effect of exercise-conditioned serum was found to be mediated through phosphorylation and cytoplasmic retention of YAP and reduced expression of downstream target genes, for example, ANKRD1 and CTGF.
|
28887324 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In silico analyses revealed increased phosphorylation of MAPK1/3, p38 and YAP, and decreased expression of p70S6K and 4E-BP1 in PIK3CA mutated compared to wild-type luminal breast cancer.
|
28886403 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer.
|
28733631 |
2017 |
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Hence, we focus on the relationship between YAP/TAZ and serine metabolism to control methylation of DNA or histone in breast cancer with LKB1 deficiency.
|
28931725 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GR activation correlates with YAP activity in human breast cancer and predicts bad prognosis in the basal-like subtype.
|
28102225 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockdown of YAP1 inhibited the extracellular acidification rates, glucose consumption, and lactate production of breast cancer cells.
|
28892790 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, resveratrol in combination with other agents that inactivate RhoA or YAP showed more marked suppression of breast cancer cell invasion compared with single treatment.
|
28232662 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Analysis of a database containing 2,072 human breast cancer samples showed that higher expressions of Yap1 correlated with a poorer outcome of a 15-year survival rate and median overall survival (mOS)in patients, especially in those with basal breast tumors without estrogen receptor 1 (ER) expression.
|
26695440 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report that the TEAD-YAP complex is not only frequently hyperactivated in liver and breast cancer, but also confers a strong oncogenic activity in gastric epithelial cells.
|
26364597 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
By examining breast cancer cell lines having both microarray gene expression and drug treatment data from the Genomics of Drug Sensitivity in Cancer and the Stand Up to Cancer datasets, we found that the elevated YAP1 mRNA expression was associated with the resistance of BCL-2 family inhibitors, but with the sensitivity to MEK/MAPK inhibitors in breast cancer cells.
|
27771839 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer.
|
26678338 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.
|
26265440 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss oncogenic activities linked with TAZ/YAP in BC, and we propose clinical strategies for investigating their role as biomarkers in the clinical setting.
|
26136233 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NRG1 stimulated YAP-dependent cell migration in breast cancer cell lines.
|
25492965 |
2014 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer.
|
23340296 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A functional variant rs1820453 in YAP1 and breast cancer risk in Chinese population.
|
24223879 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
|
23216692 |
2012 |